NantKwest Hosting Key Opinion Leader Meeting on Novel Immunotherapeutic Approaches to Address the Unmet Medical Needs of Patients with Merkel Cell Carcinoma, Triple-Negative Breast Cancer and Solid Tumors

CULVER CITY, Calif., November 27, 2019 – NantKwest, Inc. (Nasdaq: NK), a next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and other...

NantKwest Key Opinion Leader Event

KOL Lunch on Phase I & II Clinical Programs Conference Details: Date: Monday, December 2, 2019 from 12:00 PM to 2:00 PM EST This event will feature presentations from Key Opinion Leaders, George Ansstas, MD (Washington University of Medicine, St. Louis), Chaitali...